Study of LUT017 Gel for Wound Healing After Skin Lesion Removal
This is a Phase 1 research study evaluating a topical gel called LUT017 to see if it helps skin wounds heal after minor procedures. The study is for healthy adults, aged 18 and older, who are already scheduled to have two non-cancerous skin lesions, like moles, removed. After removal, one wound will receive LUT017 gel, and the other will receive a placebo gel (without active medicine). The main goal is to check for any side effects from LUT017 gel. The study aims to enroll 9 participants, but the current recruitment status is unclear. This study will help researchers understand the safety of LUT017 and how it might help wounds heal.
- Study design
- This is a Phase 1, open-label study involving 9 healthy adult participants. Each participant will have one wound treated with LUT017 gel and another with a placebo gel.
- What's involved
- You would undergo excision of two benign skin lesions and have LUT017 gel or placebo applied to the wounds. You will have follow-up visits for about 7 days after the gel is applied.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be followed for about 7 days after receiving the study drug.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Study of LUT017 Gel to Improve Healing of Skin Wounds After Removal of Benign Lesions in Healthy Adults
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Antoni Ribas, M.D., PhD · STUDY_DIRECTOR · University of California, Los Angeles
- William Zhang, MD · PRINCIPAL_INVESTIGATOR · University of California, Los Angeles
- Amanda Truong, MD, PhD · STUDY_CHAIR · University of California, Los Angeles
- Jeremy C Davis, MD · STUDY_CHAIR · University of California, Los Angeles
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Incidence of Treatment-Emergent Adverse Events (TEAEs)From Day 0 (study drug administration) through Day 7 follow-up visit (±2 days)
Safety and tolerability of a single topical application of LUT017 gel assessed by the number and severity of treatment-emergent adverse events, including local cutaneous reactions, systemic adverse events, clinically significant laboratory abnormalities, and investigator-assessed relatedness to study drug.